Quality indicators for breast cancer care

The table below shows that Legacy Cancer Institute outperforms other cancer programs on key quality benchmarks, established by the American College of Surgeons Commission on Cancer (CoC). It also shows the high percentage of our breast cancer patients treated according to the highest, nationally-recognized standards of care developed through the CoC's National Accreditation Program for Breast Centers (NAPBC). Legacy's exceptional performance in these benchmark areas are evidence that our patients receive the most up-to-date and effective treatment.

Legacy Cancer Institute outperforms its peers in key treatment areas

For women with breast cancer

Legacy Cancer Institute

Pacific Region CoC Programs

All CoC Programs

NAPBC program standard 
Needle/core biopsy is performed prior to surgical treatment for breast cancer  100%  Not available  Not available 100% 

Radiation therapy administered within 1 year of diagnosis for women under age 70 receiving breast conserving surgery

 98.1%

 85.5%

 87.8%

 100%

Combination chemotherapy considered or administered within 4 months of diagnosis for women under age 70 with AJCCTlc, Stage II or III hormone receptor negative breast cancer

 95.2%

 86.2%

 89.2%

 100%

Tamoxifen or third generation aromatase inhibitor considered or administered within 1 year of diagnosis for women with AJCCTlc, Stage ll or lll hormone receptor positive breast cancer

 99.4%

 76.3%

 82.7%

 100%

The most recent ACoS CoC quality indicators, showing how Legacy ranks against our peers. Table shows the proportion of breast cancer patients treated according to nationally recognized standards of care. (Data is the most recent available, 2011.) NAPBC data is from 2012.